These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32865979)

  • 21. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
    Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
    Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advances and controversies of statins application in prevention and treatment of hepatocellular carcinoma].
    Xu Y; Xiao P; Ba TT; Ding MM; Gao YH
    Zhonghua Zhong Liu Za Zhi; 2021 Jul; 43(7):751-755. PubMed ID: 34289568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statins in Chronic Liver Disease: Review of the Literature and Future Role.
    Pham N; Benhammou JN
    Semin Liver Dis; 2024 May; 44(2):191-208. PubMed ID: 38701856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease.
    Doumas M; Imprialos K; Dimakopoulou A; Stavropoulos K; Binas A; Athyros VG
    Curr Pharm Des; 2018; 24(38):4587-4592. PubMed ID: 30652643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
    Vargas JI; Arrese M; Shah VH; Arab JP
    Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
    Erez G; Leitersdorf E
    Eur J Vasc Endovasc Surg; 2007 Feb; 33(2):192-201. PubMed ID: 17185010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
    Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
    Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are statins 'IDEAL' for non-alcoholic fatty liver disease?
    Athyros VG; Katsiki N; Karagiannis A; Mikhailidis DP
    Curr Med Res Opin; 2014 Feb; 30(2):229-31. PubMed ID: 24127654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statin and aspirin for prevention of hepatocellular carcinoma: what are the levels of evidence?
    Carrat F
    Clin Res Hepatol Gastroenterol; 2014 Feb; 38(1):9-11. PubMed ID: 24183917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins and protein prenylation in cancer cell biology and therapy.
    Garcia-Ruiz C; Morales A; Fernandez-Checa JC
    Anticancer Agents Med Chem; 2012 May; 12(4):303-15. PubMed ID: 22413970
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
    Krysiak R; Okopień B; Herman Z
    Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study.
    Kim G; Jang SY; Nam CM; Kang ES
    J Hepatol; 2018 Mar; 68(3):476-484. PubMed ID: 29107150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium.
    Chłopicki S; Gryglewski RJ
    Pharmacol Rep; 2005; 57 Suppl():86-96. PubMed ID: 16415489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-alcoholic fatty liver disease and the statins treatment.
    Dima A; Marinescu AG; Dima AC
    Rom J Intern Med; 2012; 50(1):19-25. PubMed ID: 22788090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cirrhosis as new indication for statins.
    Bosch J; Gracia-Sancho J; Abraldes JG
    Gut; 2020 May; 69(5):953-962. PubMed ID: 32139553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Functional expression of human HMG-CoA reductase in Saccharomyces cerevisiae: a system to analyse normal and mutated versions of the enzyme in the context of statin treatment.
    Wysocka-Kapcinska M; Lutyk-Nadolska J; Kiliszek M; Plochocka D; Maciag M; Leszczynska A; Rytka J; Burzynska B
    J Appl Microbiol; 2009 Mar; 106(3):895-902. PubMed ID: 19187128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins: A Panacea to Reduce Mortality in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma?
    Shawcross DL; Suddle A
    Liver Transpl; 2022 Mar; 28(3):357-358. PubMed ID: 34837475
    [No Abstract]   [Full Text] [Related]  

  • 40. Cholesterol-independent effects of statins in inflammation, immunomodulation and atherosclerosis.
    Arnaud C; Veillard NR; Mach F
    Curr Drug Targets Cardiovasc Haematol Disord; 2005 Apr; 5(2):127-34. PubMed ID: 15853754
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.